Update shared on01 Aug 2025
Fair value Increased 14%Driven by an improvement in net profit margin and a lower future P/E multiple, Kiniksa Pharmaceuticals International’s fair value has been revised upward, with the consensus analyst price target rising from $40.83 to $45.17.
What's in the News
- Raised 2025 net product revenue guidance to $625–$640 million from prior $590–$605 million.
- Announced details for planned Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis, initiating mid-2025.
- KPL-387 trial to assess multiple dosing regimens with primary efficacy endpoints focused on time to treatment response and recurrence prevention.
- Study design includes dose-focusing (Phase 2), pivotal (Phase 3), and long-term extension components, supported by Phase 1 data.
Valuation Changes
Summary of Valuation Changes for Kiniksa Pharmaceuticals International
- The Consensus Analyst Price Target has significantly risen from $40.83 to $45.17.
- The Net Profit Margin for Kiniksa Pharmaceuticals International has significantly risen from 17.20% to 19.53%.
- The Future P/E for Kiniksa Pharmaceuticals International has fallen from 25.82x to 23.61x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.